A breakthrough medical innovation that began life at Stevenage Bioscience Catalyst has become the first non-hormonal menopause treatment in its class to be approved by the UK’s Medicines and ...

Bayer AG (BAYRY) reported second-quarter 2025 core earnings of 35 cents per American Depositary Receipt (ADR), which ...

The FDA has extended the review period for elinzanetant for the treatment of moderate to severe vasomotor symptoms due to menopause.

The FDA has extended the review period for elinzanetant for the treatment of moderate to severe vasomotor symptoms due to menopause.

The extended review for Elinzanetant is supported by data from the Phase III OASIS 1, 2, and 3 trials, which supported the drug’s efficacy in the treatment of moderate to severe vasomotor symptoms due ...

Bayer announced that the US Food and Drug Administration (FDA) has notified the company that it has extended the review period for the New Drug Application (NDA) for elinzanetant, the first neurokinin ...

Elinzanetant is the first neurokinin 1 and neurokinin 3 receptor antagonist in late-stage clinical development for the hormone-free treatment of moderate to severe vasomotor symptoms (VMS) due to ...

Elinzanetant was recently approved in the UK for the treatment of moderate to severe vasomotor symptoms (VMS or hot flashes) associated with menopause under the brand name Lynkuet.